Can a cholesterol drug help immunotherapy fight colorectal cancer?
NCT ID NCT07718490
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding the immunotherapy drug adebrelimab and the cholesterol-lowering drug simvastatin to standard chemotherapy and targeted therapy can shrink tumors in people with advanced colorectal cancer that has not responded to prior treatment. The study enrolls adults aged 18 to 75 with a specific type of colorectal cancer (MSS/pMMR) that typically does not respond to immunotherapy alone. Researchers will measure how many patients experience tumor shrinkage and how long they live without the disease worsening.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adebrelimab combined with simvastatin, bevacizumab, capecitabine, and oxaliplatin
- What this could lead to
- If successful, this combination could offer an effective first-line treatment option for the majority of colorectal cancer patients who do not respond to immunotherapy alone.
- What could go wrong
- This is a small, early-phase trial with only 43 participants, so results may not apply broadly. The drug combination also carries risks of immune-related side effects and chemotherapy toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
RECRUITINGNanjing, Jiangsu, 210008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanjing First Hospital, Nanjing Medical University Affiliated Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
- Can a simpler chemo schedule tame colorectal cancer with fewer side effects?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- Mini-Tumors grown in a dish could guide chemo choices for advanced colorectal cancer